Table 4 Treatment details, response, and subsequent course of disease
From: Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases
Patient | Age (years) | Sex | Stage | Number of treated metastases | IL-2 dose (MIU) | Weeks of treatment | Histopathologic response evaluation | Local response | Subsequent course of systemic disease, systemic therapy | Current status |
|---|---|---|---|---|---|---|---|---|---|---|
1 | 38 | F | III | 3 | 281 | 16 | Not done | 2 CR, 1 NA | VM (4 M)/T+IFN | DE |
2 | 62 | F | III | 17 | 397.5 | 57 | Done | 17 CR | Stable | AL, DF |
3 | 69 | F | III | 5 | 447 | 53 | Done | 5 CR | VM (16 M)/IFN | DE |
4 | 61 | M | III | 4 | 61 | 12 | Not done | 4 PR | VM (3 M)/T+IFN | DE |
5 | 74 | M | III | 2 | 99 | 8 | Not done | 2 CR | VM (4 M)/T+IFN | AL, DF |
6 | 59 | F | III | 3 | 18 | 2 | Not done | 3 CR | Stable | AL, DF |
7 | 83 | F | III | 1 | 18 | 4 | Not done | 1 CR | VM (6 M) | AL |
8 | 65 | M | IV | 50 | 79 | 8 | Done | 50 CR | VM (2 M)/T+IFN | DE |
9 | 63 | M | III | 11 | 287 | 18 | Done | 10 CR, 1 NA | VM (5 M)/IFN | AL |
10 | 58 | M | III | 1 | 8 | 5 | Done | 1 CR | Stable | AL, DF |
11 | 52 | F | IV* | 3 | 115 | 4 | Done | 3 CR | Further progression/V | DE |
12 | 30 | F | III | 3 | 103 | 7 | Not done | 3 CR | Further progression/BOLD | DE |
13 | 35 | F | IV* | 15 | 119.2 | 12 | Done | 15 PR | Further progression/D+IFN | DE |
14 | 68 | M | IV | 45 | 91 | 4 | Done | 45 CR | Stable | AL, DF |
15 | 60 | F | IV* | 7 | 118 | 20 | Not done | 4 NA, 3 PD | Further progression/T | AL |
16 | 66 | F | III | 5 | 18 | 2 | Not done | 5 CR | Stable | AL, DF |
17 | 64 | M | III | 1 | 15.5 | 2 | Done | 1 CR | Stable | AL, DF |
18 | 51 | F | IV* | 4 | 88 | 8 | Not done | 1 PR, 3 PD | Further progression/T+IFN | DE |
19 | 64 | F | III | 2 | 175 | 8 | Done | 1 CR, 1 PD | VM (7 M)/S+HP | AL, DF |
20 | 78 | M | III | 20 | 38.5 | 12 | Done | 20 CR | VM (2 M) | AL |
21 | 72 | F | III | 20 | 10.5 | 5 | Not done | 20 CR | Stable | AL, DF |
22 | 19 | M | IV* | 2 | 9 | 1 | Not done | 2 NA | Further progression/R | DE |
23 | 59 | M | IV* | 1 | 54 | 3 | Not done | 1 PR | Further progression/T | AL |
24 | 70 | F | III | 20 | 67.5 | 4 | Done | 20 CR | Stable | AL, LM |